Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review

  • News

Executive Summary

CMS’ Medicare Evidence Development and Coverage Advisory Committee is scheduled to meet Sept. 21 to consider whether use of anti-VEGF drugs, including Roche’s Avastin (bevacizumab) and Roche/Genentech’s Lucentis (ranibizumab), are “reasonable and necessary” for treatment of diabetic macular edema.

You may also be interested in...



MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.

MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.

Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin

Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS053637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By